-
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Cancer drug developer Boundless Bio is a pioneer in therapies that target extrachromosomal DNA. The IPO cash will support its pipeline, including a lead program on track to report preliminary data later this year.
-
Devices & Diagnostics, BioPharma
Novocure’s Electrical Cancer Therapy Shows It Can Treat Tumors in the Brain
Novocure said its “Tumor Treating Fields” met the main goal of a pivotal study enrolling non-small cell lung cancer patients with brain metastases. However, results for the electricty-based treatment fell short of statistical significance on several secondary endpoints.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Merck Drug for Heart and Lung Disorder Wins a First-in-Class FDA Approval
Merck drug Winrevair is the first in a new class of pulmonary arterial hypertension therapies that address a key signaling pathway behind the disease. The drug comes from Merck’s $11.5 billion acquisition of Acceleron Pharma.
-
AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition
AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.
-
Novo Nordisk Expands Cardio Reach by Buying Heart Drugs Biotech Cardior
Novo Nordisk’s strategy to grow beyond metabolic diseases includes expanding into adjacent areas such as cardiovascular disease. Acquiring Cardior Pharmaceuticals adds a novel RNA-based therapy that is a potential heart failure treatment.
-
Pharma, Artificial Intelligence, BioPharma
Survey: Pharma Commercial Teams Want More Data Analytics Solutions
Lack of automation is the top challenge facing commercialization teams, according to a survey of executives at U.S.-based pharma companies. The survey was conducted in late 2023 and results were reported this month.
-
FDA Nod in Duchenne Helps Wider Swath of Patients With the Rare Muscle Disease
Corticosteroids are a standard first-line treatment for Duchenne muscular dystrophy, but these drugs have many side effects. FDA approval of Italfarmaco’s Duvyzat is the first nonsteroidal drug to pass the agency’s regulatory bar for treating this rare disease.
-
Precision Medicine Startup Mirador Unveils $400M for R&D of New I&I Drugs
Mirador Therapeutics applies machine learning to human data to discover new immunology and inflammation drugs. The startup’s management includes several from the executive team of Prometheus Biosciences, an immunology biotech bought by Merck last year.
-
Startup Lands $150M for Delicate Dance Between Cancer Cells & Immune Cells
Clasp Therapeutics’ novel T cell engagers could offer advantages over others in this class of cancer immunotherapies. The startup is based on the research of Johns Hopkins University scientist Bert Vogelstein.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
AstraZeneca Joins Radiopharma Deals Spree With $2B Fusion Acquisition
AstraZeneca’s Fusion Pharmaceuticals acquisition is the latest in a wave of M&A activity that includes recent deals by Eli Lilly and Bristol Myers Squibb. The lead Fusion program is in mid-stage clinical development for treating advanced prostate cancer.
-
With MS & Fibrosis Trials Planned, J&J-Partnered Contineum Now Preps for IPO
Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.
-
Red Sea Shipping Disruptions Don’t Have Pharma Companies Seeing Red Just Yet
Generic drugs are the pharmaceutical products mainly affected by the missile attacks disrupting shipping in the Red Sea. While the extra costs borne by drug companies aren’t causing an immediate spike in product prices, experts say they’ll eventually be factored into prices if the attacks become a long-term problem.
-
A Startup’s Flexibility With ADC Cancer Drugs Attracts €128M for Clinical Trials
Tubulis’s next-generation ADC cancer drugs are designed to overcome limitations of currently available therapies in this drug class. The new financing will support clinical trial plans, but first, preclinical proof-of-concept data will be presented during the American Association for Cancer Research annual meeting.